Genome-wide association studies of survival in 1520 cancer patients treated with bevacizumab-containing regimens.
Genome-wide association studies of survival in 1520 cancer patients treated with bevacizumab-containing regimens. Int J Cancer. 2022 01 15; 150(2):279-289.